Tonix Pharmaceuticals to Participate in Two Investor Conferences in May

Rhea-AI Summary

Tonix Pharmaceuticals (Nasdaq: TNXP) will participate in two investor conferences in May 2026. CEO Seth Lederman will join fireside chats at the RBC Capital Markets Global Healthcare Conference in New York on May 19, 2026, and A.G.P.’s Annual Virtual Healthcare Conference on May 20, 2026.

Live webcasts and replays will be available on Tonix’s investor relations website.

News Market Reaction – TNXP

+4.22%

8 alerts

+4.22% Session close to close

-6.6% Trough in 1 hr 14 min

$200.44M Market Cap

0.1x Rel. Volume

In the May 13 session, TNXP gained 4.22%, reflecting a moderate positive market reaction. Argus tracked a trough of -6.6% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Tonix’s participation in two May investor conferences, showcasing its c...

Analysis

This announcement highlights Tonix’s participation in two May investor conferences, showcasing its commercial-stage CNS franchise and Phase 2–ready immunology pipeline, including TONMYA and TNX-4800. Recent filings detailed growing product revenue alongside higher losses and clarified that an S-3/A shelf remains in place. Investors may focus on how management frames commercialization progress, timelines for Phase 2 programs, and upcoming regulatory or clinical milestones referenced in prior disclosures.

Key Figures

TONMYA dose: 2.8 mg Zembrace dose: 3 mg Tosymra dose: 10 mg +5 more

8 metrics

TONMYA dose 2.8 mg Cyclobenzaprine HCl sublingual tablets for fibromyalgia

Zembrace dose 3 mg Sumatriptan injection for acute migraine

Tosymra dose 10 mg Sumatriptan nasal spray for acute migraine

RBC conference date May 19, 2026 RBC Capital Markets Global Healthcare Conference fireside chat

RBC conference time 1:35 p.m. ET Scheduled time for Tonix fireside chat

A.G.P. conference date May 20, 2026 A.G.P.’s Annual Virtual Healthcare Conference fireside chat

A.G.P. conference time 3:00 p.m. ET Scheduled time for Tonix virtual presentation

Phase 2 status Phase 2 / Phase 2 ready Multiple CNS and immunology programs, including TONMYA and TNX-4800

Historical Context

5 past events · Latest: May 06 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 06	Market access update	Positive	+8.8%	Expanded commercial payer coverage for TONMYA to ~35M U.S. lives.
Apr 29	Clinical trial plans	Positive	-2.4%	Presented TNX-4800 Phase 1 data and outlined adaptive Phase 2 study.
Apr 23	Preclinical data	Positive	-4.7%	Reported preclinical immuno-oncology results for TNX-1700 and TNX-4700.
Apr 15	PK publication	Positive	+7.4%	Published steady-state pharmacokinetics data for TONMYA after 20 days.
Mar 31	Phase 1 data	Positive	+14.3%	Presented TNX-4800 Phase 1 results and Phase 2 study outline.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent TNXP news has generally been positive, but price reactions have been mixed, with three aligned gains and two divergences where positive R&D updates were followed by declines.

Recent Company History

Over the last six weeks, Tonix reported multiple milestones: expanded commercial coverage for TONMYA on May 6, Phase 1 data and Phase 2 plans for Lyme candidate TNX-4800 on April 29 and March 31, and positive pharmacokinetic data for TONMYA on April 15. Price reactions ranged from -4.73% to +14.3%, showing that even constructive clinical and commercial updates have produced varied trading responses. Today’s conference-participation news fits within this cadence of ongoing communication rather than a discrete binary catalyst.

Key Terms

sublingual, monoclonal antibody, mAb, cd40 ligand, +4 more

8 terms

sublingual medical

"TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment"

Sublingual describes a way to take a drug or supplement by placing it under the tongue so active ingredients are absorbed through the thin tissue there directly into the bloodstream. Like taking a shortcut compared with swallowing a pill, this can produce faster effects, simpler dosing and sometimes more predictable delivery. Investors watch for sublingual formulations because they can affect a product’s market appeal, regulatory pathway, pricing and competitive positioning.

monoclonal antibody medical

"TNX-4800, a Phase 2 ready long-acting human anti-Borrelia OspA monoclonal antibody (mAb)"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

mAb medical

"anti-Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease"

A mAb (monoclonal antibody) is a lab-made protein designed to recognize and bind a specific target on cells or pathogens, like a custom-made key that fits one lock. Investors care because mAbs are often developed as therapies or diagnostic tools whose clinical trial results, regulatory approvals, production capacity, and patent status can drive significant revenue swings and affect a company’s valuation and risk profile.

cd40 ligand medical

"third-generation CD154/CD40 ligand (CD40L) inhibitor for the prevention of kidney"

CD40 ligand is a protein found on certain immune cells that acts like a switch or matchmaker, telling other immune cells to activate, produce antibodies or ramp up inflammation. Investors should care because drugs or tests that block or measure this molecule can alter immune responses, making it a common target or biomarker in treatments for autoimmune disease, transplant rejection and cancer immunotherapy—outcomes that drive clinical trial value and regulatory decisions.

cd40l medical

"third-generation CD154/CD40 ligand (CD40L) inhibitor for the prevention of kidney"

CD40L (CD40 ligand) is a protein found on the surface of certain immune cells that acts like a molecular switch, helping immune cells talk to one another and coordinate responses. Investors should care because drugs that block or mimic this switch are common targets in biotech — they can treat autoimmune diseases, prevent transplant rejection, or boost vaccines — and clinical trial results or safety issues around CD40L-targeting therapies can strongly affect a company’s value.

phase 2 medical

"Tonix is investigating TONMYA in Phase 2 clinical trials to evaluate its potential"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

prader-willi syndrome medical

"TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome"

A rare genetic disorder caused by missing or altered instructions on a specific chromosome that leads to constant hunger, low muscle tone, learning challenges, and hormonal problems; think of it as a faulty instruction manual that affects growth, appetite control, and development. Investors care because the condition creates a defined patient population, special regulatory incentives, and long-term medical needs that shape demand for therapies, diagnostics, and care services, influencing market size and risk for drug developers.

biologics medical

"product development candidates are investigational new drugs or biologics; their efficacy and safety"

Biologics are medicines made from living cells or their components rather than from simple chemical recipes, more like a handcrafted product than a mass-produced pill. They matter to investors because they often command higher prices and longer patent protection but also carry greater manufacturing, regulatory and supply risks—so a successful biologic can boost a company’s revenue significantly, while setbacks can quickly affect its stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BERKELEY HEIGHTS, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced that the management team will participate in two upcoming investor conferences in May 2026.

RBC Capital Markets Global Healthcare Conference
Fireside Chat
Participant: Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals
Location: New York, New York
Date: May 19, 2026
Time: 1:35 p.m. ET

A.G.P.’s Annual Virtual Healthcare Conference
Fireside Chat
Presenter: Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals
Location: Virtual
Date: May 20, 2026
Time: 3:00 p.m. ET

Live webcasts and replays will be available under the News & Events tab in the Investors section of the Tonix website at https://ir.tonixpharma.com/.

Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA^® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace^® Symtouch^® (sumatriptan injection 3 mg) and Tosymra^® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti-Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD154/CD40 ligand (CD40L) inhibitor for the prevention of kidney transplant rejection. In addition, Tonix is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com.

*Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners.

Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 including those relating to the completion of the offering, the satisfaction of customary closing conditions, the intended use of proceeds from the offering and other statements that are predictive in nature. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to successfully launch and commercialize TONMYA^® and any of our approved products; risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 12, 2026, and periodic reports filed with the SEC on or after the date thereof. Tonix does not undertake an obligation to update or revise any forward-looking statement. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contacts
Jessica Morris
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 799-8599

Brian Korb
astr partners
(917) 653-5122
brian.korb@astrpartners.com

Media Contacts
Deborah Elson
Tonix Pharmaceuticals
deborah.elson@tonixpharma.com

Ray Jordan
Putnam Insights
ray@putnaminsights.com  

FAQ

When will Tonix Pharmaceuticals (TNXP) present at the RBC Capital Markets Global Healthcare Conference in 2026?

Tonix Pharmaceuticals will present at the RBC Capital Markets Global Healthcare Conference on May 19, 2026, at 1:35 p.m. ET. CEO Seth Lederman will take part in a fireside chat in New York, offering insights for investors.

What is the schedule for Tonix Pharmaceuticals (TNXP) at A.G.P.’s Annual Virtual Healthcare Conference 2026?

Tonix Pharmaceuticals is scheduled for a fireside chat at A.G.P.’s Annual Virtual Healthcare Conference on May 20, 2026, at 3:00 p.m. ET. CEO Seth Lederman will present virtually to discuss the company with investors.

How can investors watch Tonix Pharmaceuticals (TNXP) May 2026 conference webcasts?

Investors can watch live webcasts and replays of Tonix’s May 2026 conference appearances under the News & Events section of the company’s investor relations website, according to Tonix. Access is available for both live and archived sessions.

Who will represent Tonix Pharmaceuticals (TNXP) at the May 2026 investor conferences?

Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will represent the company at both May 2026 conferences. He will participate in fireside chats focused on Tonix’s business and pipeline, according to the company.

What topics does Tonix Pharmaceuticals (TNXP) focus on for investors in 2026?

Tonix focuses on central nervous system and immunology treatments, including fibromyalgia, migraine, Lyme disease prevention, transplant rejection prevention, and Prader-Willi syndrome. According to Tonix, these programs will likely underpin discussions at the May 2026 investor conferences.